Zydus’s acquisition of Assertio to bolster its specialty pharma presence in US market
Upon completion of the merger, Assertio will become a wholly owned subsidiary of Zydus Lifesciences and will be delisted from the Nasdaq
Upon completion of the merger, Assertio will become a wholly owned subsidiary of Zydus Lifesciences and will be delisted from the Nasdaq
Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market
State-of-the-art facility brings next-generation imaging and minimally invasive neurointerventional capabilities to Eastern India
Backs Lifesigns in first bet and doubles down on India’s healthcare AI surge
Over 28 crore people screened, TB incidence falls sharply as Centre urges states to intensify efforts ahead of July campaign deadline
Seasoned pharmaceutical R&D leader takes on an expanded leadership role to drive innovation and strengthen Hetero’s advanced formulation development capabilities
Study will assess the safety and effectiveness of irreversible electroporation as a minimally invasive treatment option for benign prostatic hyperplasia (BPH)
New facility equipped with advanced imaging technology to support 200 additional procedures a month and benefit nearly 3,000 more patients annually
Union Health Minister calls for heightened vigilance, stronger public awareness campaigns, and district-specific action plans for the high-transmission season
Marketing leader behind growth of brands such as Cipladine, Maxirich, and Soak Shield takes on expanded responsibilities to drive portfolio growth and consumer engagement.
Subscribe To Our Newsletter & Stay Updated